Participants in a new clinical study are said to have lost an average of 3.2kg in just three months when they consumed KiOnutrime-CsG, a fat-binding ingredient for weight management applications developed by KitoZyme. The multi-centre, single-blind clinical trial took place at four different hospitals and medical research centres between late 2014 and early 2015. Healthy […]
Participants in a new clinical study are said to have lost an average of 3.2kg in just three months when they consumed KiOnutrime-CsG, a fat-binding ingredient for weight management applications developed by KitoZyme.
The multi-centre, single-blind clinical trial took place at four different hospitals and medical research centres between late 2014 and early 2015. Healthy overweight men and women aged between 18 and 65 were divided into two groups: a treatment group and a control group taking a placebo. Apart from being overweight with a BMI between 26 and 35 at the start of the trial, nobody taking part was suffering from any serious health conditions or was pregnant.
The 64 people in the treatment group were given five capsules per day, each containing 500mg of KiOnutrime-CsG. They took one capsule in the morning, two 15 minutes before lunch and two more 15 minutes before dinner. The 32 people enrolled in the control group followed the same procedure but their capsules contained a placebo. Besides these requirements, everyone continued with their regular diet and exercise patterns and all the participants kept a diary to record their experiences and encourage compliance. Out of 96 people enrolled, a total of 86 people completed the study.
The researchers observed a statistically significant gradual reduction in bodyweight in the treatment group throughout the study, compared with a baseline measured at the start. In contrast, there was no statistically significant change in the body weight of the group who received the placebo. Overall, the subjects in the treatment group lost 3.2kg of their body weight on average over 90 days, compared with the baseline. The researchers also observed statistically significant reductions in average body fat, as well as in the upper abdominal, hip and waist circumference of people consuming KiOnutrime-CsG.
“The results of this study, which will be published shortly in a peer-reviewed journal, demonstrate the clear benefits of KiOnutrime-CsG and the significant potential it offers in weight management applications globally,” said Francois Luthers, Sales & Marketing Director of KitoZyme.
Produced by KitoZyme at its manufacturing facility in Belgium, KiOnutrime-CsG works by preventing some of the fat in food from being absorbed by the body. It is a cationic (positively charged) biopolymer that binds with anionic (negatively charged) molecules such as fats and fatty acids, and obstructs the emulsification and absorption of cholesterol. Taken just a few minutes before a meal, KiOnutrime-CsG will bind dietary fat in the stomach to form a gel that is later excreted naturally without being absorbed. A previous study carried out using a lab-based model of the human gut showed that KiOnutrime-CsG can bind 42% of the fats ingested in a typical meal.
KiOnutrime-CsG is an animal-free chitosan that is completely odourless and tasteless, making it suitable for a range of applications. It dissolves in just 10 minutes in the acidic environment of the stomach. This means that a dose can be administered almost immediately before a meal, making it convenient and easy for consumers to remember to take. Most other fat binding agents need to be taken up to 30 minutes before a meal, which makes compliance more difficult.
KiOnutrime-CsG is available as an ingredient for dietary supplements in the USA, where the ingredient has GRAS status. In the European Union, it is available from KitoZyme in finished products that are classified as medical devices. KitoZyme offers a range of complete, over-the-counter solutions that are ready to be marketed as own-label or branded products. These include tablets, capsules and sticks. KiOnutrime-CsG is considered safe under the EU’s Novel Foods regulation and is already approved by the European Food Safety Authority (EFSA) to carry the health claim that it maintains normal blood LDL cholesterol at a dose of 3g per day.